Abstract
Transcriptional regulators, including the cohesin complex member STAG2, are recurrently mutated in cancer. The role of STAG2 in gene regulation, hematopoiesis, and tumor suppression remains unresolved. We show Stag2 deletion in hematopoietic stem/progenitor cells (HSPC) results in altered hematopoietic function, increased self-renewal, and impaired differentiation. ChIP-sequencing revealed that while Stag2 and Stag1 can bind the same loci, a component of Stag2 binding sites are unoccupied by Stag1 even in Stag2-deficient HSPCs. While concurrent loss of Stag2 and Stag1 abrogated hematopoiesis, Stag2 loss alone decreased chromatin accessibility and transcription of lineage-specification genes, including Ebf1 and Pax5, leading to blunted HSPC commitment to the B-cell lineage. Our data illustrate a role for Stag2 in transformation and transcriptional dysregulation distinct from its shared role with Stag1 in chromosomal segregation.
Introduction
The cohesin complex is a ring-shaped molecular machine essential for sister chromatid cohesion during cell division. However, recurrent mutations in the subunit STAG2 across various human cancers, particularly leukemias, suggest a critical role beyond chromosomal segregation. If STAG2 were solely essential for division, its loss would likely be lethal to cancer cells. This study investigates whether STAG2 possesses a unique, non-redundant role in hematopoiesis and how its loss alters the 3D genome architecture to drive oncogenic behavior.
Methodology
The researchers employed a multi-omic approach using conditional knockout mouse models and primary human samples. Key techniques included:
- Conditional Knockouts: Mice were engineered for the specific deletion of Stag1, Stag2, or both in hematopoietic stem/progenitor cells (HSPCs).
- Functional Assays: Competitive bone marrow transplants and serial replating assays evaluated the fitness and self-renewal of mutant stem cells.
- Epigenomics and 3D Structural Mapping:
- RNA-seq & scRNA-seq: Analyzed gene expression changes at bulk and single-cell resolutions.
- ATAC-seq: Measured chromatin accessibility.
- ChIP-seq: Identified specific binding sites for Stag1 and Stag2.
- Hi-C: Mapped global and local 3D genome architecture, including Topologically Associating Domains (TADs).
- Clinical Correlation: Analysis of the AML TCGA dataset and bone marrow samples from Myelodysplastic Syndrome (MDS) patients with STAG2 mutations.
Key Insights: Non-Redundant Topological Control
Partial Redundancy and Synthetic Lethality
While Stag1 and Stag2 are redundant for basic cell survival—concurrent deletion results in rapid bone marrow failure and lethality within 0.7 weeks—Stag1 cannot compensate for Stag2 in lineage-specific gene regulation.
The "Stag2-Only" Binding Sites
ChIP-seq revealed that while many binding sites are shared at TAD borders, a specific subset of genomic loci is bound exclusively by Stag2. In the absence of Stag2, these sites remain unoccupied, as Stag1 does not redistribute to these locations.
Local Architecture and Lineage Commitment
Losing Stag2 does not cause a global collapse of TADs. Instead, it disrupts local insulation and short-range DNA looping. These "Stag2-only" loops are essential for maintaining chromatin accessibility at lineage-defining genes such as Ebf1 and Pax5. Without these loops, these genes are silenced, trapping HSPCs in a state of increased self-renewal and blocking differentiation into mature B-cells.
Results
- HSPC Expansion: Stag2 deficiency led to a 2.2-fold increase in the HSPC pool, characterized by dysfunctional differentiation.
- Transcriptional Dysregulation: Integrated analysis confirmed that downregulated genes in Stag2-deficient cells correlated with reduced chromatin accessibility and loss of local DNA interactions.
- Functional Rescue: Re-expression of Ebf1 in Stag2-deficient cells successfully restored B-cell differentiation and curtailed abnormal self-renewal, confirming the mechanistic link between topological control and cell fate.
Discussion and Future Directions
This study elucidates why Stag2 loss leads to a developmental blockade in the B-cell lineage. However, given the prevalence of STAG2 mutations in myeloid leukemias, further research is needed to identify "Stag2-only" targets in other hematopoietic contexts.
Crucially, the essentiality of Stag1 for the survival of Stag2-mutant cells identifies STAG1 as a therapeutic vulnerability. Developing small-molecule inhibitors for STAG1 could provide a targeted "synthetic lethal" strategy for treating cancers harboring STAG2 mutations.
Summary updated